Immunogenicity of repeated dose 13-valent pneumococcal conjugate vaccine compared to the existing recommended protocol of pneumococcal polysaccharide vaccine in adult kidney and liver transplant patients.

Trial Profile

Immunogenicity of repeated dose 13-valent pneumococcal conjugate vaccine compared to the existing recommended protocol of pneumococcal polysaccharide vaccine in adult kidney and liver transplant patients.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics
  • Acronyms HUCH; SOT-13
  • Most Recent Events

    • 18 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Apr 2015 Planned number of patients changed from 150 to 195 as per ClinicalTrials.gov record.
    • 31 Jan 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01781871).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top